Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis
Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis
复制标题
DOI：
10.1159/000069942
复制
发表时间：
2003-01-01
期刊：
影响因子：
3.4
通讯作者：
Haney, J
中科院分区：
文献类型：
--
作者：
Finlay, AY;Salek, MS;Haney, J
背景银屑病严重影响患者的生活质量（QOL）。Amevive（R）（alefacept）是一种新型的选择性生物制剂，在一项2期研究中临床有效，并显著改善了QOL。方法：本安慰剂对照、随机3期研究采用皮肤病专用问卷[皮肤病生活质量指数（DLQI）;皮肤病生活质量量表（DQOLS）]和简明健康调查表（SF-36）（一种通用的一般健康问卷），在507例慢性斑块状银屑病患者中检查了12周疗程的肌肉注射alefacept对QOL的影响。结果：所有3项QOL测量（DLQI、DQOLS、SF-36）均表明，阿法塞15 mg在改善慢性斑块状银屑病患者的QOL方面显著优于安慰剂。此外，alefacept 15 mg组患者的所有3项QOL指标的QOL改善幅度相似。结论：这项研究的结果是一个重要的补充银屑病治疗的生活质量文献。
Background. Psoriasis profoundly affects patient quality of life (QOL). Amevive(R) (alefacept), a novel and selective biologic agent, was clinically effective and significantly improved QOL in a phase 2 study. Methods:The present placebo-controlled, randomized phase 3 study examined the effects of a 12-week course of intramuscular alefacept on QOL in 507 patients with chronic plaque psoriasis using both dermatology-specific questionnaires [Dermatology Life Quality Index (DLQI); Dermatology Quality of Life Scales (DQOLS)l and the Short Form-36(TM) Health Survey (SF-36), a generic, general health questionnaire. Results:All 3 QOL measures (DLQI, DQOLS, SF-36) demonstrated that alefacept 15 mg was significantly more effective than placebo in improving QOL in patients with chronic plaque psoriasis. In addition, the improvements in QOL for patients in the alefacept 15 mg group were of similar magnitude for all 3 QOL measures. Conclusion: The findings of this study are an important addition to the QOL literature for psoriasis treatments.